Sugentech Inc.

Equities

A253840

KR7253840003

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
5,380 ^KRW	-1.28%		-5.45%	-30.58%

2023	Tranche Update on Sugentech Inc.'s Equity Buyback Plan announced on March 29, 2023.	CI
2023	Tranche Update on Sugentech Inc.'s Equity Buyback Plan announced on March 29, 2023.	CI

NH Investment & Securities Co., Ltd. and BNK Securities Co., Ltd. acquired 2.84% stake in Sugentech Incorporated from Korea Development Bank for KRW 3.4 billion.

October 07, 2018

NH Investment & Securities Co., Ltd. (KOSE:A005940) and BNK Securities Co., Ltd. acquired 2.84% stake in Sugentech Incorporated (XKON:A253840) from Korea Development Bank for KRW 3.4 billion on September 28, 2018. A total of 0.17 million shares will be acquired as part of the deal for KRW 20,200 per share.

NH Investment & Securities Co., Ltd. (KOSE:A005940) and BNK Securities Co., Ltd. completed the acquisition of 2.84% stake in Sugentech Incorporated (XKON:A253840) from Korea Development Bank on September 28, 2018.

Latest news about Sugentech Inc.

Tranche Update on Sugentech Inc.'s Equity Buyback Plan announced on March 29, 2023.	Dec. 28	CI
Tranche Update on Sugentech Inc.'s Equity Buyback Plan announced on March 29, 2023.	Dec. 28	CI
Sugentech Inc.'s Equity Buyback announced on March 29, 2023, has closed with 1,453,532 shares, representing 9.11% for KRW 11,999.87 million.	Dec. 27	CI
Sugentech Inc.'s Equity Buyback Plan Extended till December 28, 2023.	23-09-26	CI
Tranche Update on Sugentech Inc.'s Equity Buyback Plan announced on March 29, 2023.	23-07-03	CI
Tranche Update on Sugentech Inc.'s Equity Buyback Plan announced on March 29, 2023.	23-07-03	CI
Sugentech Inc. announces an Equity Buyback for KRW 12,000 million worth of its shares.	23-03-29	CI
Sugentech Inc. authorizes a Buyback Plan.	23-03-28	CI
Sugentech Inc.(KOSDAQ:A253840) added to S&P Global BMI Index	21-09-20	CI
Sugentech Inc. announced that it has received KRW 34.9997715 billion in funding from a group of investors	21-07-15	CI
Sugentech Inc. announced that it expects to receive KRW 34.9997715 billion in funding from a group of investors	21-07-07	CI
Avellino and Sugentech Announce Strategic Collaboration	20-08-25	CI
Sugentech Inc. announced that it has received KRW 10 billion in funding from a group of investors	19-09-22	CI
Sugentech Inc. announced that it expects to receive KRW 10 billion in funding from a group of investors	19-09-18	CI
Samsung Securities Co.,Ltd. acquired 3.41% stake in Sugentech Incorporated from The Innopolis Job Creation Fund, a fund of Innopolis Partners LLC for KRW 4.9 billion.	19-03-14	CI
NH Investment & Securities Co., Ltd. and BNK Securities Co., Ltd. acquired 2.84% stake in Sugentech Incorporated from Korea Development Bank for KRW 3.4 billion.	18-10-07	CI
Sugentech Incorporated announced that it has received KRW 2.9999828 billion in funding	18-09-02	CI
Sugentech Incorporated announced that it expects to receive KRW 2.9999828 billion in funding	18-08-22	CI
Sugentech Incorporate completed the acquisition of K-MAC BIO CENTER Corp. from Korea Materials & Analysis Corp..	17-07-14	CI
Sugentech Incorporate announced that it has received KRW 4.000008 billion in funding from Korea Materials & Analysis Corp.	17-06-19	CI
Sugentech Incorporate entered into a contract to acquire K-MAC BIO CENTER Corp. from Korea Materials & Analysis Corp. for KRW 16.7 billion.	17-06-14	CI
Sugentech Incorporate announced that it has received KRW 12.400008 billion in funding from Korea Development Bank, ETRI Holdings Co., Ltd.	17-06-12	CI

Chart Sugentech Inc.

Duration

Period

More charts

Company Profile

Sugentech Incorporate is a Korea-based company mainly engaged in the production and sale of in-vitro diagnostic test reagents. The Company is involved in the manufacturing and sale of in vitro diagnostic test reagents, point-of-care testing (POCT) products, folic acid products under the name of SOLGAR, as well as molecular diagnostic reagents. The in vitro diagnostic test reagents are for personal use and are sold under the name SUREARLY. The POCT products are for professional use and are sold under the name INCLIX. In addition, the Company is engaged in therapeutic drug monitoring, as well as drug analysis method development. The Company distributes its products within the domestic market and to overseas markets, including Indonesia.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
SUGENTECH INC.	-30.58%	59.68M
BIOMÉRIEUX	+0.89%	12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-10.29%	7.61B
DIASORIN S.P.A.	+1.78%	5.41B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.16%	4.51B
LANTHEUS HOLDINGS, INC.	+5.74%	4.49B
10X GENOMICS, INC.	-50.70%	3.29B
ANDON HEALTH CO., LTD.	+12.21%	2.73B
VITROLIFE AB	-16.13%	2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.50%	1.73B

Diagnostic & Testing Substances